There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Felty's syndrome (FS) is a rare association of rheumatoid arthritis (RA), neutropenia
and splenomegaly. Mechanisms of neutropenia in FS are unclear but involve both innate
and humoral immunity, impaired granulopoiesis and decreased granulocyte half-life.
Several treatments have been used without clear efficiency. We report a patient with
FS efficiently treated with rituximab (RTX), the monoclonal anti-CD20 antibody. A
literature review of FS treated with RTX was performed.